Assessing Antibody-Dependent Cell-Mediated Cytotoxicity

Our Director of R&D and Technical Services, Dr. Catriona Thomson recently spoke to ‘Pharmaceutical Technology’ about¬†the challenges of developing and validating an ADCC methodology, including the difference between the classical ADCC assay and the reporter bioassay. To read the full article please click here.

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.